Receptors, Purinergic P2Y12
"Receptors, Purinergic P2Y12" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of purinergic P2Y receptors that have a preference for ADP binding and are coupled to GTP-BINDING PROTEIN ALPHA SUBUNIT, GI. The P2Y12 purinergic receptors are found in PLATELETS where they play an important role regulating PLATELET ACTIVATION.
MeSH Number(s)
D12.776.543.750.100.700.720.500.300
D12.776.543.750.720.700.720.750.300
D12.776.543.750.810.720.750.300
Concept/Terms
Receptors, Purinergic P2Y12- Receptors, Purinergic P2Y12
- P2Y12 Receptors, Purinergic
- Purinergic P2Y12 Receptors
- P2Y(ADP) Receptor
- P2Y(T) Receptor
- P2Y12 Purinoceptors
- Purinoceptors, P2Y12
- Purinoceptor P2T
- P2T, Purinoceptor
- Purinoceptor P2Y12
- P2Y12, Purinoceptor
- P2T Purinoceptor
- Purinoceptor, P2T
- P2Y12 Purinoceptor
- Purinoceptor, P2Y12
Below are MeSH descriptors whose meaning is more general than "Receptors, Purinergic P2Y12".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.100]
- Receptors, Purinergic [D12.776.543.750.100.700]
- Receptors, Purinergic P2 [D12.776.543.750.100.700.720]
- Receptors, Purinergic P2Y [D12.776.543.750.100.700.720.500]
- Receptors, Purinergic P2Y12 [D12.776.543.750.100.700.720.500.300]
- Receptors, Neurotransmitter [D12.776.543.750.720]
- Receptors, Purinergic [D12.776.543.750.720.700]
- Receptors, Purinergic P2 [D12.776.543.750.720.700.720]
- Receptors, Purinergic P2Y [D12.776.543.750.720.700.720.750]
- Receptors, Purinergic P2Y12 [D12.776.543.750.720.700.720.750.300]
- Receptors, Purinergic [D12.776.543.750.810]
- Receptors, Purinergic P2 [D12.776.543.750.810.720]
- Receptors, Purinergic P2Y [D12.776.543.750.810.720.750]
- Receptors, Purinergic P2Y12 [D12.776.543.750.810.720.750.300]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Purinergic P2Y12".
This graph shows the total number of publications written about "Receptors, Purinergic P2Y12" by people in Harvard Catalyst Profiles by year, and whether "Receptors, Purinergic P2Y12" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 5 | 5 |
| 2010 | 0 | 5 | 5 |
| 2011 | 0 | 1 | 1 |
| 2012 | 4 | 3 | 7 |
| 2013 | 3 | 3 | 6 |
| 2014 | 3 | 1 | 4 |
| 2015 | 5 | 0 | 5 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 6 | 7 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 2 | 4 |
| 2021 | 0 | 2 | 2 |
Below are the most recent publications written about "Receptors, Purinergic P2Y12" by people in Profiles.
-
Severe, Intolerable Fatigue Associated with Hyperresponse to Clopidogrel. World Neurosurg. 2021 12; 156:e374-e380.
-
Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model. Thromb Res. 2021 04; 200:133-140.
-
Advances in the Pharmacogenomics of Antiplatelet Therapy. Am J Ther. 2020 Sep/Oct; 27(5):e477-e484.
-
Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy. Acta Neuropathol Commun. 2020 05 19; 8(1):72.
-
Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative. Circ Cardiovasc Qual Outcomes. 2020 03; 13(3):e006275.
-
Laboratory assessments of therapeutic platelet inhibition in endovascular neurosurgery: complication prediction using the VerifyNow P2Y12 assay and thromboelastography with platelet mapping. J Neurosurg. 2020 Feb 21; 134(3):884-892.
-
Targetable purinergic receptors P2Y12 and A2b antagonistically regulate bladder function. JCI Insight. 2019 08 22; 4(16).
-
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2019 08 26; 12(16):1521-1537.
-
GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 09 28; 8(1):14529.
-
Microglia inhibit photoreceptor cell death and regulate immune cell infiltration in response to retinal detachment. Proc Natl Acad Sci U S A. 2018 07 03; 115(27):E6264-E6273.